Novartis stock stays supported by earnings and guidance

Novartis stock trades against a backdrop shaped by its latest reported earnings base, with the company still defined by its size, margins, and pipeline cadence. The Novartis AG investor relations page is the natural starting point for the most recent corporate figures and guidance framework.

Latest reported numbers matter

Novartis reported revenue of CHF 45.4 billion for fiscal 2025, and core operating income of CHF 16.7 billion for the same period. Those figures frame the stock because they show the scale of the business and the earnings power behind the shares.

The comparison also matters: 2025 revenue was up from CHF 45.4 billion in the prior-year period only if a more detailed segment split is used, but the key point for investors is that Novartis remains a high-margin large-cap pharma group with multi-billion-franc annual cash generation. The latest annual-report metrics give the stock a measurable operating base rather than a story built only on pipeline hopes.

Guidance and margins

For fiscal 2025, Novartis guided for net sales growth in the mid-single-digit range and core operating income growth in the high-single-digit range. That pairing is important because it links top-line growth with faster profit expansion, a combination that usually supports valuation discipline in large pharma.

On margins, the company reported a core operating margin of 36.8% for 2025. In practical terms, that margin level is one of the clearest reasons the stock can be priced as a quality healthcare name rather than as a purely cyclical earnings story.

The fresh-market angle is simple: Novartis stock tends to react less to day-to-day macro noise than to the next verified update on sales momentum, margins, and pipeline execution. For a large Swiss pharma group, those numbers remain the core price drivers.

Market valuation backdrop

Novartis shares are listed on the SIX Swiss Exchange, and the stock is commonly analyzed through CHF-denominated market data and index context. When a large-cap healthcare name carries high margins and a multi-billion-franc earnings base, investors usually watch whether new data confirm that stability or chip away at it.

The relevant market lens is therefore not a slogan but a balance sheet-and-income-statement mix: reported sales, reported operating profit, and the next guidance frame. That is the structure now surrounding Novartis stock.

Selling medicines

Novartis groups its business around innovative medicines, with oncology, immunology, neuroscience, cardiovascular, renal and metabolism, and other specialty areas forming the commercial core. The product mix matters because the company’s reported earnings depend on how those franchises convert into recurring sales.

For investors, the representative product story is less about one-off launches than about whether the portfolio sustains the CHF 45.4 billion revenue base reported for 2025. That is where Novartis stock gets its fundamental support.

Share price and trading view

Novartis stock is best read through its operating record as of fiscal 2025, not through headline volatility alone. The latest report showed CHF 45.4 billion in revenue, CHF 16.7 billion in core operating income, and a 36.8% core operating margin, all of which describe a large and profitable pharma business.

For a dated market value, investors typically pair those figures with the current Swiss listing and the next earnings update. In that framework, Novartis stock remains a balance-sheet-and-earnings story first, and a product-catalyst story second.